biotech

Entelos Collaborates With Novartis On In Silico Drug Trials

Filed in archive Corporate and Industrial News , Diagnostics, Methodologies and Instrumentation , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics on August 23, 2006

Entelos Collaborates With Novartis On In Silico Drug Trials
Before drugs make it to the commercial production, they are first tested in vitro i.e., under laboratory conditions. And then they go through in vivo, or clinical trials involving animal and ultimately, human models. But in between these two stages, did you know that there is also an optional stage called in silico?
Entelos, Inc. is a US-based life sciences company which creates computer models of human physiology designed to reduce the risk, time, and cost of drug discovery and development. The Company's portfolio of proprietary computer models, known as PhysioLab systems, have helped its pharmaceutical customers validate novel drug targets, select and develop compounds, optimize clinical trials, evaluate in-licensing candidates, and better position existing products in competitive markets.

Entelos just entered into a research agreement with Novartis AG to predict the effect of Novartis' drug candidates on "virtual patients" using Entelos' PhysioLab® platforms.

[Photo: Entelos]

Permalink: Entelos Collaborates With Novartis On In Silico Drug Trials

Tags: bioinformatics  drug 

Vote for Entelos Collaborates With Novartis On In Silico Drug Trials:

  • Currently 6.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.00 out of 1 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells